Novartis, Genentech file suit alleging illegal importation of prescription drug

Core Viewpoint - Novartis and Genentech have filed a lawsuit against SHARx and a Canadian pharmacy for illegally importing their allergy medication Xolair into the U.S., which violates FDA regulations [1][2][4]. Group 1: Legal Action - The lawsuit targets SHARx, an alternative funding program, and a Canadian pharmacy for the importation of Xolair, an injectable medication for severe asthma and allergies [2]. - The plaintiffs are seeking a court order to halt the importation of the drug, which they argue circumvents FDA regulations [4]. Group 2: Drug Safety Concerns - The lawsuit emphasizes that biological medicines like Xolair require careful handling due to their complex composition, which makes them vulnerable to contamination and degradation [3]. - Federal authorities have previously stated that importing medications from foreign markets is illegal and poses health risks to patients [5]. Group 3: Market Context - The lawsuit follows a CNBC investigation revealing the rise of alternative funding programs (AFPs) that connect patients with cheaper medication options, often sourced from overseas at reduced prices [5].